Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155218784762
Abstract: Azacitidine, a deoxyribonucleic acid hypomethylating agent, is used in the treatment of myelodysplastic syndrome. Common adverse effects of azacitidine include bone marrow suppression, injection site reactions, nausea, vomiting, diarrhea, and fatigue. This report focuses on… read more here.
Keywords: azacitidine; myelodysplastic syndrome; report; pleuropericardial effusion ... See more keywords